Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis.

Abstract

N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous antifibrotic peptide. We found that suppression of AcSDKP and induction of dipeptidyl peptidase-4 (DPP-4), which is associated with insufficient levels of antifibrotic microRNA (miR)s in kidneys, were imperative to understand the mechanisms of fibrosis in the diabetic kidneys. Analyzing streptozotocin (STZ)-induced diabetic mouse strains, diabetic CD-1 mice with fibrotic kidneys could be differentiated from less-fibrotic diabetic 129Sv mice by suppressing AcSDKP and antifibrotic miRs (miR-29s and miR-let-7s), as well as by the prominent induction of DPP-4 protein expression/activity and endothelial to mesenchymal transition. In diabetic CD-1 mice, these alterations were all reversed by AcSDKP treatment. Transfection studies in culture endothelial cells demonstrated crosstalk regulation of miR-29s and miR-let-7s against mesenchymal activation program; such bidirectional regulation could play an essential role in maintaining the antifibrotic program of AcSDKP. Finally, we observed that AcSDKP suppression in fibrotic mice was associated with induction of both interferon-γ and transforming growth factor-β signaling, crucial molecular pathways that disrupt antifibrotic miRs crosstalk. The present study provides insight into the physiologically relevant antifibrotic actions of AcSDKP via antifibrotic miRs; restoring such antifibrotic programs could demonstrate potential utility in combating kidney fibrosis in diabetes.

• Authors: Swayam Prakash Srivastava, Sen Shi, Megumi Kanasaki, Takako Nagai, Munehiro Kitada, Jianhua He, Yuka Nakamura, Yasuhito Ishigaki, Keizo Kanasaki, Daisuke Koya
• Journal: Scientific reports (Sci Rep) Vol. 6 Pg. 29884 (07 18 2016) ISSN: 2045-2322 [Electronic] England
• PMID: 27425816 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Dipeptidyl-Peptidase IV Inhibitors
• MicroRNAs
• Oligopeptides
• Transforming Growth Factor beta
• Fibroblast Growth Factor 1
• Interferon-gamma
• Dipeptidyl Peptidase 4
• Dpp4 protein, mouse
• goralatide

Topics

• Animals
• Diabetes Mellitus (drug therapy, genetics, pathology)
• Dipeptidyl Peptidase 4 (metabolism)
• Dipeptidyl-Peptidase IV Inhibitors (pharmacology, therapeutic use)
• Endothelial Cells (drug effects, metabolism)
• Fibroblast Growth Factor 1 (metabolism)
• Fibrosis
• Humans
• Interferon-gamma (pharmacology)
• Kidney (pathology)
• Mice
• MicroRNAs (genetics, metabolism)
• Microvessels (pathology)
• Models, Biological
• Oligopeptides (pharmacology, therapeutic use)
• Phosphorylation (drug effects)
• Signal Transduction (drug effects)
• Transforming Growth Factor beta (metabolism)
• Up-Regulation (genetics)